第7章 パイプラインポートフォリオ

第8章 市場情勢

第9章 市場区分：分子タイプ別

第10章 市場区分：投与経路別

第11章 地理区分

第12章 市場促進要因

第13章 促進要因の影響

第14章 市場の課題

第15章 促進要因と課題の影響

第16章 市場動向

第17章 ベンダー情勢

第18章 主要ベンダー分析

AstraZeneca

Celgene

Eli Lilly

F. Hoffmann-La Roche

Pfizer

第19章 付録

第20章 Technavioについて

図表

※ このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Product Code: IRTNTR7475

About non-small cell lung cancer therapeutics

Non-small cell lung cancer occurs when normal cells grow and multiply without control after undergoing a cell transformation. Lung cancer is the leading cause of cancer deaths worldwide, and the incidence of lung cancer is increasing significantly. Lung cancer is the common cause of mortality and morbidity not only in developed countries but also in developing countries. One of the most common types of lung cancer is non-small cell lung cancer. It grows and spreads quite slowly. Smoking is considered as a major cause of lung cancer, although lung cancer also occurs in non-smokers. There are three main types of non-small cell lung cancer: squamous cell (epidermoid) carcinoma, adenocarcinoma, and large cell (undifferentiated) carcinoma. Some of the common symptoms associated with non-small cell lung cancer are chest pain, a cough that does not go away, coughing up blood, fatigue, loss of appetite, losing weight without trying, shortness of breath, and wheezing.

Technavio's analysts forecast the global non-small cell lung cancer therapeutics market to grow at a CAGR of 6.77% over the period 2014-2019.

Covered in this report

The report covers the current scenario and the growth prospects of the global non-small cell lung cancer therapeutics market for the period of 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used for the treatment of non-small cell lung cancer.

Technavio's report, Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and Europe; it also covers the landscape of the global non-small cell lung cancer therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

Americas

APAC

Europe

Key vendors

AstraZeneca

Celgene

Eli Lilly

F. Hoffmann-La Roche

Pfizer

Other Prominent Vendors

Abbvie

Aetna

Agennix

Amgen

BetaPharma

Bionumerik Pharmaceuticals

Boehringer Ingelheim

Bristol-Myers Squibb

CBT Pharma

Celldex Therapeutics

Dainippon Pharma

Eisai Pharmaceuticals

GlaxoSmithKline

Helsinn

IMClone Systems

IsisPharma

Kadmon

Kyowa Hakko Kirin

MabVax Therapeutics

Merck

Novartis

OncoGenex

OSI Pharmaceuticals

Peregrine

Pierre Fabre

Qiagen

Sanofi

Synta Pharmaceuticals

Teva Pharmaceuticals

Key market driver

Promising drug pipeline

For a full, detailed list, view our report

Key market challenge

High cost of therapy

For a full, detailed list, view our report

Key market trend

Personalized medicine

For a full, detailed list, view our report

Key questions answered in this report

What will the market size be in 2019 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?